This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter
by Zacks Equity Research
Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.
BIIBPositive Net Change JNJPositive Net Change RHHBYPositive Net Change MRKNegative Net Change
biotechs
Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Bristol Myers (BMY), among others.
INCYPositive Net Change BMYPositive Net Change VRTXPositive Net Change CRSPNegative Net Change ANIXNegative Net Change MORPositive Net Change
biotechs
Roche (RHHBY) Q1 Sales Affected by Biosimilars & COVID-19
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2021 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
REGNPositive Net Change RHHBYPositive Net Change GILDNegative Net Change RGENPositive Net Change
biotechs pharmaceuticals
Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership
by Zacks Equity Research
Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.
VRTXPositive Net Change EDITNegative Net Change NTLAPositive Net Change CRSPNegative Net Change
biotechs
Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.
ILMNPositive Net Change OMINo Net Change COONegative Net Change HCANegative Net Change
biotechs earnings medical
Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe
by Zacks Equity Research
Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change EBSPositive Net Change
biotechs
Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.
MRKNegative Net Change SGENPositive Net Change RGENPositive Net Change ASLNNegative Net Change
biotechs
Incyte (INCY), MorphoSys Initiate Dosing in Lymphoma Study
by Zacks Equity Research
Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.
INCYPositive Net Change BMYPositive Net Change RGENPositive Net Change MORPositive Net Change
biotechs
Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.
RHHBYPositive Net Change MRKNegative Net Change MRNAPositive Net Change BMYPositive Net Change
biotechs pharmaceuticals
Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra
by Zacks Equity Research
Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.
RHHBYPositive Net Change NVSPositive Net Change BNTXNegative Net Change CVACNegative Net Change
biotechs medical
Will J&J ETFs Suffer on Latest COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs that can see adverse impacts as Johnson & Johnson's coronavirus vaccine sees a setback amid the worsening pandemic conditions.
JNJPositive Net Change XLVPositive Net Change IYHPositive Net Change IHEPositive Net Change FTXHPositive Net Change IEIHPositive Net Change
biotechs etfs medical
Moderna (MRNA) Gives Pipeline Update, to Initiate New Pivotal Study
by Zacks Equity Research
Moderna (MRNA) is developing 14 mRNA-based vaccine candidates in different stages of clinical development. Interim data from ongoing cytomegalovirus and RSV vaccine studies are promising.
JNJPositive Net Change PFEPositive Net Change MRNAPositive Net Change BNTXNegative Net Change
biotechs
Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.
PFEPositive Net Change MRKNegative Net Change EXELPositive Net Change BMYPositive Net Change
biotechs
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.
BIIBPositive Net Change REGNPositive Net Change GILDNegative Net Change BMYPositive Net Change
biotechs
Waters (WAT) Teams Up With Genovis, Boosts Biopharma Reach
by Zacks Equity Research
Waters (WAT) collaborates with Genovis for developing automated biotherapeutic characterization workflows.
ADIPositive Net Change WATPositive Net Change APositive Net Change DBXNegative Net Change
biotechs tech-stocks
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
by Zacks Equity Research
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
MRNAPositive Net Change GERNNegative Net Change AVIRNo Net Change CDMOPositive Net Change
biotechs
Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer
by Zacks Equity Research
The FDA grants accelerated approval to Gilead's (GILD) Trodelvy for treating adult patients with locally-advanced or metastatic urothelial cancer.
GILDNegative Net Change RGENPositive Net Change NBRVPositive Net Change ASLNNegative Net Change
biotechs
Is J&J's COVID-19 Vaccine Setback a Boon for Other Players?
by Zacks Equity Research
J&J's (JNJ) competitors in COVID-19 vaccine space are anticipated to gain from suspension of its vaccine in the United States, following very few cases of blood clots.
JNJPositive Net Change
biotechs pharmaceuticals
vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.
RGENPositive Net Change NBRVPositive Net Change VTVTNegative Net Change ASLNNegative Net Change
biotechs
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
by Zacks Equity Research
Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.
PFEPositive Net Change MRNAPositive Net Change RGENPositive Net Change MYOVPositive Net Change
biotechs
Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study
by Zacks Equity Research
Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.
RHHBYPositive Net Change MRKNegative Net Change MRNAPositive Net Change BMYPositive Net Change
biotechs
Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail
by Zacks Equity Research
Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.
REGNPositive Net Change RHHBYPositive Net Change GSKPositive Net Change VIRPositive Net Change
biotechs
Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.
SGENPositive Net Change RGENPositive Net Change NBRVPositive Net Change GMABPositive Net Change
biotechs
Do Options Traders Know Something About Inovio (INO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
INOPositive Net Change
biotechs medical
Celcuity (CELC) Soars on Agreement With Pfizer & Study Data
by Zacks Equity Research
Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.
PFEPositive Net Change NVSPositive Net Change PBYINegative Net Change CELCNegative Net Change
biotechs